Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis

Satoshi Kitai, Masatoshi Kudo, Naoshi Nishida, Namiki Izumia, Michiie Sakamoto, Yutaka Matsuyama, Takafumi Ichida, Osamu Nakashima, Osamu Matsui, Yonson Kuh, Norihiro Kokudo, Masatoshi Makuuchi for the Liver Cancer Study Group of Japan

ABSTRACT

Background & Aims: Hepatocellular carcinoma (HCC) with decompensated liver cirrhosis (LC) is a life-threatening condition, which is amenable to liver transplantation (LT) as the standard first-line treatment. However, the application of LT can be limited due to a shortage of donor livers. This study aimed to clarify the effect of non-surgical therapy on the survival of patients with HCC and decompensated LC.

Methods: Of the 58,886 patients with HCC registered in the nationwide survey of the Liver Cancer Study Group of Japan (January 2000–December 2005), we included 1,344 patients with primary HCC and Child-Pugh (C-P) grade C for analysis in this retrospective study. Among the patients analyzed, 108 underwent LT, 273 were treated by local ablation therapy (LAT), 370 were treated by transarterial chemoembolization (TACE), and the remaining patients were treated with best supportive care.
(TACE), and 593 received best supportive care (BSC). The effect of LT, LAT, and TACE on overall survival (OS) was analyzed using multivariate and propensity score analyses. **Results:** Patient characteristics did not differ significantly between each treatment group and the BSC group, after propensity score matching. LAT (hazard ratio [HR] = 0.568; 95% confidence interval [CI], 0.40-0.80) and TACE (HR = 0.691; 95% CI, 0.50-0.96) were identified as significant contributors to OS if the C-P score was less than 11 and tumor conditions met the Milan criteria. **Conclusions:** For patients with HCC within the Milan criteria and with a C-P score of 10 or 11, locoregional treatment can be used as a salvage treatment if LT is not feasible.

**Introduction**

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and the second leading cause of death from cancer [1]. Approximately 80% of patients with HCC have chronic hepatitis and liver cirrhosis (LC), which is attributed to chronic infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) [2]. Despite recent advancements in antiviral therapy for viral hepatitis, the prognosis of patients with decompensated LC remains poor, especially in cases with concomitant HCC [3]. Therefore, in addition to tumor stage, it is critical to evaluate liver function for the management of patients with HCC [4, 5].

For HCC with preserved liver function, several treatment options are available including partial hepatectomy [6], liver transplantation (LT) [7–11], local ablation therapy (LAT) [12], and transarterial chemoembolization (TACE) [13–16]. In particular, LT is recommended for patients with advanced LC of Child-Pugh (C-P) grade C and an early stage of HCC [5, 7, 10, 17]. However, the application of LT to patients with HCC has been limited because of the shortage of donor livers. In addition, systemic therapies including sorafenib are not feasible without any survival benefit in HCC cases with C-P grade C [18]. Therefore, it is necessary to know whether conventional locoregional treatment for HCC, such as LAT and TACE, can improve survival even in patients with HCC and C-P grade C. However, there has been a lack of evidence for the value of locoregional treatments in such patients with decompensated LC although several reports state some survival benefit in a small-sized retrospective study [19, 20]. Because best supportive care (BSC) is recommended for patients with HCC and C-P grade C, when LT is not applicable, the benefits of BSC in comparison to locoregional treatments should be assessed in the context of overall survival (OS) in these patients.

We address this important issue using a systematic and multi-pronged approach with a large cohort of patients with HCC and C-P grade C using a Japanese nationwide database. The aim of this study was to evaluate the utility of non-surgical treatment for patients suffering from primary HCC with decompensated LC.

**Materials and Methods**

**Patient Characteristics**

Patients included in the analysis were registered in the database of a nationwide survey of the Liver Cancer Study Group of Japan (LCSGJ). The data collection and registration of patients with HCC included in this analysis were performed with the approval of each patient’s institution. Obtaining informed consent from patients was not required because of the retrospective design of the study.

The patients were diagnosed with HCC on the basis of histological or radiological examinations as well as clinical criteria [5, 21–23]. A histological examination was performed if the tumor did not present...
with typical radiological features or if an increase in any HCC-specific tumor markers (alpha-fetoprotein [AFP], Lens culinaris agglutinin-reactive AFP and des-gamma-carboxy prothrombin) was not detected.

Of the 58,886 patients who were registered in the LCSGJ as having newly diagnosed HCC between January 2000 and December 2005, 42,905 were eligible for this analysis because all of the following data were available in the database including: C-P grade and its constitutive parameters (serum bilirubin level, serum albumin level, prothrombin time [PT], ascites, and hepatic encephalopathy), age, sex, status of HBV and HCV, tumor size, number of tumors, tumor-, node-metastasis (TNM) stage, and treatment modalities (i.e., LT, LAT, TACE, or BSC).

Among them, a total of 1,344 patients were classified as having C-P grade C and were enrolled in this study. Among the enrolled patients, 656 were identified with a C-P score of 10. Likewise, the numbers of patients with C-P scores of 11, 12, 13, 14, and 15 were 384, 186, 73, 38, and 7, respectively. The diagnosis of HCC was mainly established by imaging studies; 189 out of 1,344 patients were diagnosed by biopsy or via operatively extracted specimens. Tumors of 828 patients were within the Milan criteria, whereas 516 did not meet the criteria. To determine the eligibility for locoregional treatment for HCC according to the C-P score, we further classified cases of HCC into two groups as follows: the ‘lower score’ group (C-P score=10 or 11, n=603) and the “higher score” group (C-P score =12-15, n=143). There were no patients who were treated with radiofrequency ablation (RFA) combined with TACE in this study. The details of the clinical data of the patients are summarized in the tables 1 and 2.

Statistical Analysis

First, we determined which factors significantly affected the OS of patients with HCC and C-P grade C. Accordingly, we compared the OS of patients categorized according to clinical background using Kaplan-Meier analysis, and univariate parameters were analyzed using the log-rank test. Patients were censored at the time of their last clinical visit or death not due to HCC. Variables with a p value of <0.05 on univariate analysis were further subjected to the multivariate analysis using the Cox proportional-hazards regression model to determine independent contributors to OS. Patient characteristics were compared among different treatment groups using Pearson’s chi-square test for categorical variables and the Student’s t-test for continuous variables.

In order to avoid selection bias of the treatment due to the different backgrounds of patients with HCC, we applied propensity score analyses, which allowed the normalization of patients’ characteristics between each treatment group. Propensity score analyses were performed for the two group pairs, LAT vs. BSC, and TACE vs. BSC, to evaluate the benefit of treatment in comparison to BSC. The Kaplan-Meier method and log-rank test were also used for survival analyses of matched patients. Because the propensity score analysis could not compare three groups (i.e., LAT, TACE, and BSC), the utility was compared between each treatment and BSC, according to the hazard ratio (HR) of treatment compared to BSC.

Results

Clinical Factors Associated with Survival in Patients with HCC and C-P Grade C LC

To evaluate which factors contributed to the improvement of OS in patients with HCC and C-P grade C, we analyzed the association between the duration of OS and each clinical parameter. The univariate analysis revealed that a younger age, smaller tumor size, lower AFP level, lower C-P score, lower TNM stage, and receipt of treatment were identified as significant factors contributing to an increased duration of OS (p<0.0001 for each by log-rank test, table 3). The status of hepatitis virus infection also showed borderline significance (p=0.0424).

We subsequently performed a multivariate analysis, which showed that receipt of treatment (p<0.0001), smaller tumor size (p=0.0002), lower AFP levels (p=0.0010), lower TNM stage (p<0.0001), and lower C-P score (p=0.0070) were independent contributors to longer survival (see table 4). In a comparison of OS among the BSC, LT, LAT, and TACE groups with C-P grade C, the LT group showed the longest OS compared to the LAT (p=0.0271) and TACE (p<0.0001) groups, respectively. Conversely, the LAT (p<0.0001) and TACE (p<0.0001) groups showed longer OS than the BSC group for each comparison (see fig. 1a). Similarly, in patients within the Milan criteria, the LT group showed the longest OS than the LAT (p=0.0079) and
TACE (p=0.0010) groups, respectively. On the other hand, the LAT (p<0.0001) and TACE (p<0.0001) groups showed longer OS than the BSC group for each comparison (see fig. 1b).

To determine whether locoregional treatment for HCC showed benefit regardless of the baseline C-P score, we further excluded the LT focusing on the impact of LAT and TACE. We also conducted separate survival analyses in both the lower C-P score and higher C-P score groups. In the lower C-P score group, both the LAT and TACE groups showed longer OS than the BSC group (p<0.0001 for both LAT and TACE groups; see fig. 2a), suggesting that these locoregional treatments might have a survival benefit for patients with HCC and C-P score 10 or 11. The median OS (95% confidence interval [CI]) of patients who received BSC and locoregional treatments were 4.0 months (range 2.9-5.1 months) for the BSC group, 26.0 months (range 22.4-29.6 months) for the LAT group, and 17.0 months (range 14.6-19.4 months) for the TACE group, respectively (p<0.0001 for each comparison; see fig. 2a).

Similarly, in patients with HCC with a higher C-P score, both the LAT and TACE groups had longer OS than the BSC group. The median OS (95% CI) of patients who received BSC and locoregional treatment groups were 2.0 months (range 1.5-2.5 months) for the BSC group, 11.0 months (range 9.4-12.6 months) for the LAT group, and 14.0 months (range 11.9-16.1 months) for the TACE group, respectively (p<0.0001 for each comparison except for LAT vs. TACE; see fig. 2b).
Survival Benefit of Locoregional Treatment for HCC in Patients with Lower and Higher C-P Scores

We also conducted a multivariate analysis to determine the independent variables that had an effect on the duration of OS in patients with HCC and lower C-P scores. Notably, a longer OS was observed even in patients who received locoregional treatment compared to those who received BSC (p<0.0001 for all variables; HR and 95% CI: 0.338 and 0.25-0.45 for LAT vs. BSC, and 0.462 and 0.36-0.58 for TACE vs. BSC, respectively). Tumor size (≤2.0 cm vs. ≥3.1 cm) and the AFP level were also associated with improved OS, with p values of <0.0001 (HR 0.595; 95% CI, 0.45-0.77) and 0.0004 (HR 0.665; 95% CI, 0.53-0.83), respectively (table 5).

For the patients with higher C-P scores, LAT and TACE also had a survival benefit (p=0.0014, HR and 95% CI=0.361 and 0.17-0.68 for LAT vs. BSC, p=0.0018, HR and 95% CI=0.517 and 0.33-0.78 for TACE vs. BSC, respectively). Lower AFP level were also associated with improved OS, with a p value of <0.0001 (HR=0.533; 95% CI, 0.37-0.76). However, tumor size (≤2.0 vs. ≥3.1) showed borderline significance on survival with a p value of 0.0664 (HR=0.662; 95% CI, 0.35-1.03; table 6).

Table 2. Characteristics of patients with HCC in each treatment group with C-P scores of 12–15

<table>
<thead>
<tr>
<th>Background factors</th>
<th>BSC</th>
<th>LAT</th>
<th>TACE</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=93</td>
<td>n=22</td>
<td>n=28</td>
<td>n=143</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60</td>
<td>26</td>
<td>8</td>
<td>12</td>
<td>46</td>
</tr>
<tr>
<td>≥60</td>
<td>67</td>
<td>14</td>
<td>16</td>
<td>97</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>60</td>
<td>17</td>
<td>19</td>
<td>96</td>
</tr>
<tr>
<td>Female</td>
<td>33</td>
<td>5</td>
<td>9</td>
<td>47</td>
</tr>
<tr>
<td>Hepatitis B and C virological status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B−, C+</td>
<td>47</td>
<td>14</td>
<td>19</td>
<td>80</td>
</tr>
<tr>
<td>B+, C−</td>
<td>15</td>
<td>3</td>
<td>3</td>
<td>21</td>
</tr>
<tr>
<td>B+, C+</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>B−, C−</td>
<td>24</td>
<td>4</td>
<td>5</td>
<td>33</td>
</tr>
<tr>
<td>Maximum tumor size (cm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2.0</td>
<td>38</td>
<td>13</td>
<td>10</td>
<td>61</td>
</tr>
<tr>
<td>2.1–3.0</td>
<td>35</td>
<td>7</td>
<td>12</td>
<td>54</td>
</tr>
<tr>
<td>3.1–5.0</td>
<td>20</td>
<td>2</td>
<td>6</td>
<td>28</td>
</tr>
<tr>
<td>No. of tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>66</td>
<td>18</td>
<td>20</td>
<td>104</td>
</tr>
<tr>
<td>≥2</td>
<td>27</td>
<td>4</td>
<td>8</td>
<td>39</td>
</tr>
<tr>
<td>AFP (ng/ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤200</td>
<td>47</td>
<td>7</td>
<td>25</td>
<td>79</td>
</tr>
<tr>
<td>&gt;200</td>
<td>54</td>
<td>7</td>
<td>12</td>
<td>73</td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>24</td>
<td>10</td>
<td>6</td>
<td>40</td>
</tr>
<tr>
<td>II</td>
<td>56</td>
<td>11</td>
<td>18</td>
<td>85</td>
</tr>
<tr>
<td>III</td>
<td>13</td>
<td>1</td>
<td>4</td>
<td>18</td>
</tr>
</tbody>
</table>
Locoregional Treatment of HCC Showed a Survival Benefit in Cases with C-P Score 10 or 11 by Propensity Score Analyses

The results of the multivariate analysis may be attributed to selection bias of the treatment based upon differences in clinical background inherent to retrospective analyses. As a consequence, we performed analyses using an unbiased method to confirm the benefit of locoregional treatment. Accordingly, we applied propensity score analyses between the BSC and locoregional treatment groups (i.e., LAT and TACE), specifically for HCC cases that met the Milan criteria for tumor status. After propensity score matching, there were no significant differences in the background characteristics between BSC and LAT groups (table 7), as well as between the BSC and TACE groups (table 8), suggesting that these were suitable cohorts for the unbiased analyses.

Table 3. Univariate analysis of risk factors for survival in patients with HCC with C-P grade C-LC

<table>
<thead>
<tr>
<th>Background factor</th>
<th>n=1344</th>
<th>Median survival time (months)</th>
<th>Survival rate (%)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60</td>
<td>432</td>
<td>18</td>
<td>57.9</td>
<td>19.9</td>
</tr>
<tr>
<td>≥60</td>
<td>911</td>
<td>9</td>
<td>43.3</td>
<td>14.9</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>897</td>
<td>11</td>
<td>48.0</td>
<td>18.8</td>
</tr>
<tr>
<td>Female</td>
<td>447</td>
<td>11</td>
<td>47.9</td>
<td>21.1</td>
</tr>
<tr>
<td>Hepatitis B and C virological status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B−, C+</td>
<td>803</td>
<td>11</td>
<td>46.2</td>
<td>18.7</td>
</tr>
<tr>
<td>B+, C−</td>
<td>204</td>
<td>12</td>
<td>49.1</td>
<td>24.4</td>
</tr>
<tr>
<td>B+, C+</td>
<td>25</td>
<td>16</td>
<td>59.4</td>
<td>12.4</td>
</tr>
<tr>
<td>B−, C−</td>
<td>262</td>
<td>13</td>
<td>51.2</td>
<td>21.2</td>
</tr>
<tr>
<td>Maximum tumor size (cm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2.0</td>
<td>441</td>
<td>15</td>
<td>57.3</td>
<td>36.9</td>
</tr>
<tr>
<td>2.1–3.0</td>
<td>335</td>
<td>16</td>
<td>57.2</td>
<td>31.7</td>
</tr>
<tr>
<td>&gt;3.1</td>
<td>568</td>
<td>4</td>
<td>28.2</td>
<td>13.1</td>
</tr>
<tr>
<td>No. of tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solitary</td>
<td>768</td>
<td>11</td>
<td>48.3</td>
<td>21.4</td>
</tr>
<tr>
<td>Multiple</td>
<td>576</td>
<td>11</td>
<td>47.5</td>
<td>17.0</td>
</tr>
<tr>
<td>AFP (ng/ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤200</td>
<td>448</td>
<td>13</td>
<td>53.3</td>
<td>27.4</td>
</tr>
<tr>
<td>&gt;200</td>
<td>315</td>
<td>9</td>
<td>26.5</td>
<td>14.0</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes (LT, LAT and TACE)</td>
<td>541</td>
<td>18</td>
<td>62.4</td>
<td>27.4</td>
</tr>
<tr>
<td>No (BSC)</td>
<td>803</td>
<td>3</td>
<td>25.7</td>
<td>6.9</td>
</tr>
<tr>
<td>C-P score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 or 11</td>
<td>1040</td>
<td>13</td>
<td>52.5</td>
<td>20.9</td>
</tr>
<tr>
<td>12–15</td>
<td>304</td>
<td>5</td>
<td>32.7</td>
<td>15.0</td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>283</td>
<td>11</td>
<td>59.2</td>
<td>28.1</td>
</tr>
<tr>
<td>II</td>
<td>496</td>
<td>10</td>
<td>48.9</td>
<td>18.9</td>
</tr>
<tr>
<td>III</td>
<td>301</td>
<td>9</td>
<td>48.8</td>
<td>12.9</td>
</tr>
<tr>
<td>IV</td>
<td>264</td>
<td>11</td>
<td>45.1</td>
<td>16.5</td>
</tr>
</tbody>
</table>
After matching, 124 pairs of patients were eligible for the comparison of OS between the BSC and LAT groups in the cohort of C-P score 10 or 11 (table 7); the median follow-up period and 25th-75th percentiles are as follows: 11.0 months and 15.1±12.9 months for the LAT group and 7.0 months and 10.6±12.0 months for the BSC group, respectively. Importantly, patients who underwent LAT showed a lower risk of death than did patients who underwent BSC (p=0.0014, HR=0.568; 95% CI, 0.40-0.80: fig. 3a). The 1-, 2-, and 3-year OS rates of the BSC and LAT groups were 53.1%, 31.4%, and 15.0%, versus 71.9%, 58.5%, and 36.3%, respectively. Similarly, 127 pairs of patients were eligible for OS comparison between the BSC and TACE groups (table 8). The results indicated that the TACE group had a longer OS than the BSC group, even after propensity score matching (median follow-up period and 25th-75th percentiles: 7.0 months and 10.2±11.6 months for the TACE group and 10.0 months and 14.7±13.9 months for the BSC group, respectively; fig. 3b). The HR of receiving TACE for patient survival was 0.691 (95% CI, 0.50–0.96; p=0.0289) compared to BSC. The 1-, 2-, and 3-year OS rates of the BSC and TACE groups were 56.9%, 33.8%, and 15.0%, versus 63.8%, 39.9%, and 22.9%, respectively.

Assessment of Survival Benefit of Locoregional Treatment for HCC by Propensity Score Matching Analyses in Cases with C-P Score 12–15

We also performed propensity analyses for patients with HCC and C-P scores of 12-15. After propensity score matching, 19 patients were eligible for the BSC versus LAT group analysis, and 49 patients were eligible for the BSC versus TACE group analysis. On comparison of OS between locoregional treatment groups and the BSC group, there were no significant differences for OS duration between the LAT and BSC groups (p=0.201, HR=0.601; 95% CI,
0.27-1.36; fig. 3c). Similarly, there were no significant differences for OS duration between the TACE and the BSC groups (p = 0.0549; HR = 0.626; 95% CI, 0.38-1.03; fig. 3d).

**Discussion**

The prognosis of HCC with decompensated LC is still unsatisfactory, and LT is the only recommended treatment for patients with HCC and C-P grade C. However, even in patients with HCC meeting the Milan criteria, LT might not be applicable because of the shortage of donor livers. Conversely, the recent developments of novel therapeutic devices help to achieve minimal deterioration of liver function after locoregional treatment [24–27]. From this perspective, it is necessary to re-evaluate the efficacy of locoregional treatments for HCC with decompensated LC, which has been a controversial issue to date. Here, we demonstrate that the locoregional treatments can be effectively used for the treatment of HCC with decompensated LC if the C-P score is 11 or less.

In the present study, the univariate and multivariate analyses revealed that smaller tumor size, lower C-P score, lower serum AFP level, lower TNM stage and receipt of non-surgical HCC treatment were significant factors contributing to an increase in OS. This suggests that these treatments may improve the survival of patients with HCC and C-P grade C. The LT group showed a significantly longer OS than locoregional treatment groups as previously reported [11, 17, 28]. Among patients with a lower C-P score, a longer OS was also observed in patients who underwent locoregional treatment compared to patients who received BSC. For patients with higher C-P scores, LAT, and TACE were also identified as carrying a survival benefit, suggesting that locoregional treatment for HCC may contribute to improvement in OS in these cases.

However, as is inherent with retrospective analyses, the bias of treatment selection can lead to unexpected results regarding the contribution of locoregional treatment to an in-
creased duration of OS. For example, age, background liver function, and the number and size of tumors may affect the selection of treatment. Therefore, we further applied a less-biased method using propensity score matching, and normalized the patients’ backgrounds. After the matching, locoregional treatment also showed a significant association with longer survival as compared to the BSC groups in the lower C-P score group. Although there has been a lack of evidence regarding the benefit of locoregional treatment in patients with HCC and C-P grade C, refined techniques using new devices for RFA and TACE may contribute to an improvement in survival, even in patients with HCC that have decompensated LC. To the contrary, in the cohort of higher C-P scores of 12-15, locoregional treatment did not produce a survival benefit, suggesting that LT is the only current treatment showing survival benefit. To further confirm the ineligibility of locoregional treatment in the C-P score 12-15 group, we analyzed the intra-group causes of death as follows: 22 of 44 patients (50%) in the locoregional treatment group

Table 5. Multivariate analysis of risk factors for survival in patients with a C-P score of 10 or 11

<table>
<thead>
<tr>
<th>Variable</th>
<th>HR</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAT vs. BSC</td>
<td>0.338</td>
<td>0.25–0.45</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>TACE vs. BSC</td>
<td>0.462</td>
<td>0.36–0.58</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60 vs. ≥60</td>
<td>0.949</td>
<td>0.74–1.19</td>
<td>0.6679</td>
</tr>
<tr>
<td>Maximum tumor size (cm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2.0 vs. 2.1–3.0</td>
<td>1.18</td>
<td>0.88–1.58</td>
<td>0.2590</td>
</tr>
<tr>
<td>≤2.0 vs. ≥3.1</td>
<td>0.595</td>
<td>0.45–0.77</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>AFP (ng/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤200 vs. &gt;200</td>
<td>0.665</td>
<td>0.53–0.83</td>
<td>0.0004</td>
</tr>
<tr>
<td>Number of tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>solitary vs. multiple</td>
<td>0.985</td>
<td>0.79–1.21</td>
<td>0.8935</td>
</tr>
</tbody>
</table>
died of hepatic failure and 13 patients (29.5%) died of cancer; 93 of 136 patients (50.2%) in the BSC group died of hepatic failure and 55 patients (40.4%) died of cancer. This supports the idea that the leading cause of death of the patients with C-P scores of 12-15 was hepatic failure, and cancer-related death was not the main cause even in the BSC group. Therefore it is conceivable that any intervention without improvement of liver decompensation is unlikely to be tolerated, or it will affect the survival for this patient group.

Although the data suggest a survival benefit of locoregional treatment in patients with HCC along with lower scores of C-P grade C, there are certain limitations in this study. First, as the nature of retrospective studies, there may be bias regarding the effect of treatment on OS, even after propensity score matching. For example, the source database is potentially flawed, since only stronger/healthier C-P grade C patients would see a physician and hence become registered. Moreover, significant selection bias occurred at the time of treatment decisions, because stronger/healthier patients tended to be treated. Second, propensity score analyses were performed only for patients with HCC within the Milan criteria in terms of tumor status. Therefore, a treatment benefit for patients with HCC beyond these criteria was not identified in this study. Third, the analysis did not include performance status, a factor that may impact on survival in patients with HCC. Although it was possible that the majority of the patients included in this study should be of a performance status of 0 or 1, the effect of performance status on survival in the treatment of HCC also needs to be confirmed in the future. However, even with these limitations, the results of this study provide sample evidence for the development of future prospective studies.

In conclusion, we provide evidence of a treatment benefit with LAT and TACE in patients with HCC within the Milan criteria and with C-P scores of 10 or 11. The results presented here are of clinical importance because BSC is the only recommended therapy in patients with HCC who have deterioration in liver function. Our data indicate that LAT or TACE could be used as a salvage treatment if LT is not applicable.

### Table 6. Multivariate analysis of risk factors for survival in patients with a C-P score of 12-15

<table>
<thead>
<tr>
<th>Variable</th>
<th>HR</th>
<th>95% CI</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAT vs. BSC</td>
<td>0.361</td>
<td>0.17–0.68</td>
<td>0.0014</td>
</tr>
<tr>
<td>TACE vs. BSC</td>
<td>0.517</td>
<td>0.33–0.78</td>
<td>0.0018</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60 vs. ≥60</td>
<td>0.89</td>
<td>0.59–1.30</td>
<td>0.5674</td>
</tr>
<tr>
<td><strong>AFP (ng/ml)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤200 vs. &gt;200</td>
<td>0.533</td>
<td>0.37–0.76</td>
<td>0.0008</td>
</tr>
<tr>
<td><strong>Maximum tumor size (cm)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2.0 vs. 2.1–3.0</td>
<td>0.957</td>
<td>0.52–1.73</td>
<td>0.8879</td>
</tr>
<tr>
<td>≤2.0 vs. ≥3.1</td>
<td>0.622</td>
<td>0.35–1.03</td>
<td>0.0664</td>
</tr>
</tbody>
</table>
Table 7. Comparison of patient characteristics between the BSC and LAT groups with C-P score 10 or 11, matched by propensity score.

<table>
<thead>
<tr>
<th>Background factors</th>
<th>BSC n=124</th>
<th>LAT n=124</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60</td>
<td>35</td>
<td>35</td>
<td>1</td>
</tr>
<tr>
<td>≥60</td>
<td>89</td>
<td>89</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>80</td>
<td>75</td>
<td>0.5119</td>
</tr>
<tr>
<td>Female</td>
<td>44</td>
<td>49</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B and C virological status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B−, C+</td>
<td>85</td>
<td>83</td>
<td>0.7645</td>
</tr>
<tr>
<td>B+, C−</td>
<td>14</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>B+, C+</td>
<td>1</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>B−, C−</td>
<td>20</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Maximum tumor size (cm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2</td>
<td>69</td>
<td>72</td>
<td>0.8605</td>
</tr>
<tr>
<td>2.1–3.0</td>
<td>47</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>3.1–5.0</td>
<td>8</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>No. of tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>91</td>
<td>90</td>
<td>0.8863</td>
</tr>
<tr>
<td>2–3</td>
<td>33</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>52</td>
<td>54</td>
<td>0.9636</td>
</tr>
<tr>
<td>II</td>
<td>56</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>16</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Bilirubin (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;2.0</td>
<td>31</td>
<td>27</td>
<td>0.8303</td>
</tr>
<tr>
<td>2.0–3.0</td>
<td>41</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>&gt;3.0</td>
<td>52</td>
<td>55</td>
<td></td>
</tr>
<tr>
<td>Albumin (g/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;3.5</td>
<td>0</td>
<td>1</td>
<td>0.5694</td>
</tr>
<tr>
<td>2.8–3.5</td>
<td>46</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>&lt;2.8</td>
<td>78</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>PT (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;70</td>
<td>4</td>
<td>7</td>
<td>0.645</td>
</tr>
<tr>
<td>40–70</td>
<td>107</td>
<td>105</td>
<td></td>
</tr>
<tr>
<td>&lt;40</td>
<td>13</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Ascites</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>44</td>
<td>40</td>
<td>0.86458</td>
</tr>
<tr>
<td>Responsive</td>
<td>53</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>Unresponsive</td>
<td>27</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Encephalopathy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>69</td>
<td>70</td>
<td>0.9361</td>
</tr>
<tr>
<td>Mild</td>
<td>36</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>Coma</td>
<td>19</td>
<td>17</td>
<td></td>
</tr>
</tbody>
</table>
Table 8. Comparison of patient characteristics between the BSC and TACE groups with C-P score 10 or 11, matched by propensity score.

<table>
<thead>
<tr>
<th>Background factors</th>
<th>BSC n=127</th>
<th>TACE n=127</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of Patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60</td>
<td>38</td>
<td>32</td>
<td>0.3995</td>
</tr>
<tr>
<td>≥60</td>
<td>89</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>81</td>
<td>79</td>
<td>0.7949</td>
</tr>
<tr>
<td>Female</td>
<td>46</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B and C virological status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B−, C+</td>
<td>83</td>
<td>86</td>
<td>0.4087</td>
</tr>
<tr>
<td>B+, C−</td>
<td>13</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>B+, C+</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>B−, C−</td>
<td>26</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>Maximum tumor size (cm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2</td>
<td>58</td>
<td>58</td>
<td>0.9828</td>
</tr>
<tr>
<td>2.1–3.0</td>
<td>48</td>
<td>49</td>
<td></td>
</tr>
<tr>
<td>3.1–5.0</td>
<td>21</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>No. of tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>84</td>
<td>85</td>
<td>0.8942</td>
</tr>
<tr>
<td>2–3</td>
<td>43</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>39</td>
<td>36</td>
<td>0.6549</td>
</tr>
<tr>
<td>II</td>
<td>64</td>
<td>71</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>24</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Bilirubin (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;2.0</td>
<td>35</td>
<td>31</td>
<td>0.8488</td>
</tr>
<tr>
<td>2.0–3.0</td>
<td>43</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>&gt;3.0</td>
<td>49</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>Albumin (g/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;3.5</td>
<td>2</td>
<td>3</td>
<td>0.8886</td>
</tr>
<tr>
<td>2.8–3.5</td>
<td>41</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>&lt;2.8</td>
<td>84</td>
<td>82</td>
<td></td>
</tr>
<tr>
<td>PT (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;70</td>
<td>7</td>
<td>10</td>
<td>0.7462</td>
</tr>
<tr>
<td>40–70</td>
<td>106</td>
<td>104</td>
<td></td>
</tr>
<tr>
<td>&lt;40</td>
<td>14</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Ascites</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>34</td>
<td>32</td>
<td>0.8772</td>
</tr>
<tr>
<td>Responsive</td>
<td>50</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>Unresponsive</td>
<td>43</td>
<td>41</td>
<td></td>
</tr>
<tr>
<td>Encephalopathy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>76</td>
<td>75</td>
<td>0.8867</td>
</tr>
<tr>
<td>Mild</td>
<td>43</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>Coma</td>
<td>8</td>
<td>10</td>
<td></td>
</tr>
</tbody>
</table>
Grant Support

This work was supported by the Health Labor Sciences Research Grant from The Ministry of Health, Labour and Welfare (H22-Clinical Oncology-General-015), Japan.

Competing Interests

The authors have no competing interests to declare.
Author Contributions

SK, NN, and MK designed the studies, wrote the initial version of the paper, and revised the manuscript. SK, NN, NI, MS, YM, TI, ON, OM, YK, NK, MM, and MK interpreted the data, performed the statistical analyses, and helped with acquisition of data. MK organized collaborations, obtained funding, supervised data collection. SK, NN, NI, MS, YM, TI, ON, OM, YK, NK, MM, and MK helped with acquisition of data.

References


